Stevanato Group Launches US Technology Excellence Center in Boston
Italian-based Stevanato Group, a leading producer of pharmaceutical glass containers and provider of integrated capabilities for drug delivery systems, has officially inaugurated its Technology Excellence Center (TEC) in Boston, MA.
The new Center provides a full-service approach to support biopharma companies along the drug development journey, from early phase development to commercialization, helping them overcome container-closure system hurdles. With growing demand for biologic therapies in the US, the Boston-based laboratory is well positioned to offer integrated development and analytical services to support local biopharma companies in their drug development journey.
“We built on our analytical laboratory experience in our HQs in Italy, to create the first Technology Excellence Center in Boston. We took this step also in the US thanks to the positive feedback received from our customers. They confirmed our capability to work with them as true partners, integrating both our and their technical teams and analytical competencies. As a result, they benefited from an optimized drug development process, reduced time-to-market, increased flexibility, and reduced total cost of ownership. US TEC represents a unique business model that we wish to replicate in other regions,” said Franco Stevanato, CEO.
“We are excited to open the doors of our new Technology Excellence Center right here in Boston at the heart of the biotech community. Given its location, the Technology Excellence Center can easily integrate with the value chain of US customers, by partnering with them at an early stage. We can anticipate challenges and present viable, robust solutions that save development time and resources,”added Paolo Patri, Stevanato Group Chief Technology Officer.
Leveraging the Group’s extensive knowledge in material science of glass, plastics, and rubber, the US TEC will cover one of the most binding decisions for biopharma industry players: how to select the primary container for a biopharmaceutical product.
“Massachusetts continues to attract life sciences companies from across the globe, who come here to access our leading academic and medical centers, diverse talent, a supportive government, and a robust startup community,” said Robert K. Coughlin, President & CEO, MassBio. “We are thrilled to welcome Stevanato Group to the #1 life sciences cluster in the world and are confident their Technology Excellence Center will support the diverse needs of biopharma companies as they seek to bring new therapies to patients.”
Stevanato Group has more than 70 years of expertise in glass primary container manufacturing, with extensive background knowledge of glass primary packaging design and technology. Since 2014, its interdisciplinary team of technicians and scientists in Italy has been building upon this knowledge with a wide range of testing, from container performance to chemical analysis, container interaction, and surface characterization.
The company has also strengthened its offer at the US TEC through a network of strategic partnerships with container closure integrity (CCI) testing provider, Pfeiffer Vacuum, Extractables & Leachables testing with Nelson Labs, and small-scale fill & finish with COLANAR.
Established in 1949, Stevanato Group is the world’s largest, privately-owned designer and producer of glass primary packaging for the pharmaceutical industry. From its outset, the Group has developed its own glass converting technology to ensure the highest standards of quality. The Group comprises a wide set of capabilities dedicated to serving the biopharmaceutical and diagnostic industries: from glass containers with its historical brand Ompi, to high-precision plastic diagnostic and medical components, to contract manufacturing for drug delivery devices, to vision inspection systems, assembly, and packaging equipment. The Group also provides analytical and testing services to study container closure integrity and integration into drug delivery devices, streamlining the drug development process. Thanks to its unique approach as a one-stop-shop, Stevanato Group can offer an unprecedented set of solutions to biopharma companies for a faster time to market and a reduced total cost of ownership. For more information, visit www.stevanatogroup.com.
Total Page Views: 589